IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: IFN-α therapy alone delayed disease progression and prolonged overall survival, and in the 1990s, IFN-α became a standard therapy for CML patients who were not suitable candidates for bone marrow transplantation [107].